bcma car-nk 92 cells
Cell therapyexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2019 (NCT03940833)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- BCMAImmunity, passive
BCMA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06926985 | Early Phase 1 (Phase 1) | Jul 30, 2025 | Jieyang People's Hospital |
| NCT06242249 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2024 | Shahid Beheshti University of Medical Sciences |
| NCT05008536 | Early Phase 1 (Phase 1) | Oct 1, 2021 | People's Liberation Army of China, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Xinqiao Hospital of Chongqing |
| NCT03940833 | Phase 1/Phase 2 (Phase 2) | May 31, 2019 | Shanghai Asclepius Meditec Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jieyang People's Hospital | Academic/Hospital | 1 | 1 | 1 | 2025 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2021 |
| Shahid Beheshti University of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Shanghai Asclepius Meditec Inc. | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | For profit | 1 | 0 | 1 | 2021 |
| Xinqiao Hospital of Chongqing | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1